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Clinical Experience with Radioisotopic 
Powered Cardiac Pacemakers 
Nicho las P. D. S m y t h , M D , * T o m a s H e r n a n d e z , M D a n d A l v i n J o h n s o n , C V T 
Significant increase in the useful lifetime of 
the implantable cardiac pacemaker has been 
made possible by the development of a 
radioisotope power source. This paper reports 
experience with two models, the AEC-ARCO 
Nu-5 (fixed rate) and the Medtronic Model 
9000 (ventricular inhibited demand). Five of 
the former models were implanted in 1973, 
and six of the latter more recently. Both types 
of units have functioned well. 
•Resident 1951-55. Now at Prince George's 
General Hospital, Cheverly, MD, and The 
George Washington University School of 
Medicine, Washington, DC. 
Address reprint requests to Dr. Smyth at 106 
Irving Street, NW, Washington, DC 20010. 
I N C R E A S I N G the longevity of the im-
plantable pulse generator is the most 
important single goal in pacing today. It 
has been possible to extend greatly the 
life of the convent ional Rubin-Mallory 
ce l l by r e d u c i n g pu lse gene ra to r 
output^'- ' or reduc ing pulse w id th ,^ ' ^ 
each combined wi th reduct ion in elec-
t r o d e sur face a rea . ' Rechargeable 
nickel-cadmium cells and l i th ium iodide 
cells are also being studied as sources of 
longer life f rom chemical batteries. 
The development of the radioisotopic 
power source, however, has provided 
the possibil ity of ten, twenty, or more 
years of useful power which makes pos-
sible the development of a real " l i fe -
t i m e " pacemaker. 
D u r i n g the past year , t w o rad io -
isotopic pulse generators have become 
available in the LJnited States for clinical 
testing under study protocols control led 
by the Atomic Energy Commission. 
The first involved the AEC-ARCO Nu-5 
fixed rate pulse generator and the sec-
o n d , the Medtronic Model 9000 ventr icu-
lar inhibi ted demand pulse generator. 
Materials and Methods 
The AEC-ARCO Nu-5 pulse generator 
is a f ixed rate unipolar unit del ivering 73 
±2 pulses per minute of 1.6 ±0.1 mil-
l isecond durat ion and not more than 8 
nor less than 4 mil l iamperes into a 500 
ohm load. 
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Figure 1 
Cutaway drawing of the AEC-ARCO nuclear 
pulse generator. 
anode for pacing; a small area on top , 
containing the circuitry and lead recep-
tacle is potted in clinical grade epoxy. 
The uni t is designed to fit a unipolar 
Cordis pacemaker lead (Figure 2). 
Maximum specified radiation f rom the 
pacemaker is 5 millirads per hour at its 
surface and less than 0.3 millirads at 5 
cent imeters f rom its surface. Of this, 
neutron contr ibut ion is not more than 
1.5 millirads per hour at the surface and 
not more than 0.1 mil l irad per hour at 5 
cen t imeters f rom the sur face. These 
maximum specified dose rates in mi l-
l i rads c o r r e s p o n d to a m a x i m u m 
specified biological dose rate of 1.2 mi l-
l irems per hour at 5 centimeters f rom the 
surface and 18.5 mil l i rems per hour at 
the surface. The radiation dose at the 
surface is 6 mrem/hr and is not consid-
ered c l in ica l ly s ign i f i cant . These are 
maximum specified dose rates. The unit 
has demonstrated high reliability in ex-
tensive in vi tro and in vivo test ing. ' 
Figure 2 
Photograph of complete unit with lead. 
The electrical energy is derived by the 
thermocouple conversion of heat gener-
ated f rom the decay of plutonium-238 
(initially 0.4 grams) which has a half life 
of 87.8 years. There are six tape assem-
blies of 88 metallic thermocouples each 
arranged in a series-parallel configura-
t ion to deliver approximately 2.2 volts 
and 230 ±10% microwatts at the begin-
ning of life (Figure 1). 
The electronic pulse generator and the 
electrical energy source are each sealed 
and then hermet ical ly sealed to each 
other. Most of the external surface of the 
uni t is t i t an i um, wh ich serves as the 
The clinical protocol requires that the 
pacers be imp lan ted in pat ients w i t h 
comple te heart b lock on ly , since the 
AEC-ARCO Nu-5 unit is a f ixed rate unit. 
The patients must have a life expectancy 
of at least 10 years, and must sign papers 
al lowing recovery of the pulse generator 
by the AEC at t ime of death. Follow-up of 
the patient involves frequent checks of 
pacemaker rate fo r t he rest of t he 
patient's l ife. A contro l series of the pa-
tients using conventional pacers is re-
quired — one for each nuclear pacer im-
planted. 
The Medtronic Model 9000 is a ven-
tr icular inhib i ted demand bipolar unit 
(Figure 3). Basic rate is 72 beats per min-
ute. This wi l l drop to 62 beats per minute 
when the hysteresis mode is operat ing. 
Ou tpu t is 5.5 volts into a 500 ohm load. 
Sensitivity is 1.5 mil l ivolts and refractory 
per iod is 280 mil l iseconds. 
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Figure 3 
Photograph of Medtronic 9000 nuclear pulse 
generator. 
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Figure 4 
Cutaway drawing of the Medtronic 9000 nu-
clear pulse generator. 
The thermoelectr ic generator uses Pu 
238. Electrical energy is derived f rom the 
heat of isotope decay through a ther-
mop i l e . The resultant vol tage is am-
pli f ied by a DC-DC converter to provide 
a signal of significant ampl i tude to cap-
ture the myocard ium. The isotope is 
sealed in four metal containers. Radiation 
emissions are very similar to the AEC-
ARCO unit and are not considered any 
hazard (Figure 4). 
Like the AEC-ARCO pacer this unit has 
undergone extensive testing prior to re-
lease for clinical tr ial . Prior to release for 
study in the United States some 500 of 
these un i ts had been i m p l a n t e d in 
Europe and Sou th Amer i ca w i t h no 
known failure up to two years. 
The Medtronic protocol allows the in-
sertion of the unit in any patient over the 
age of 18 years w h o requ i res a 
pacemaker for any rhythm disturbance. 
The patient must have a life expectancy 
of 10 years or more. Permanent fol low-
up and ult imate recovery of the units are 
required. A contro l series is required of 
four patients w i th convent ional battery 
powered units for each one receiving a 
nuclear unit . 
In June and July of 1973, five AEC-
ARCO pulse generators were implanted 
as replacement units in patients aged 40 
to 69, all of w h o m had been paced for 
several years, and were known to be in 
stable third degree heart block. Conven-
t iona l un ipo la r pacemakers were in -
serted in five patients at about the same 
t ime as controls. These patients were not 
all in complete heart block and were 
older. It was impossible to f ind a strictly 
comparable group of patients that could 
provide a meaningful contro l group. 
Be tween N o v e m b e r 1973 and July 
1974, six Medtronic 9000 units were im-
planted in patients w i th complete heart 
b lock, intermit tent heart block and sick 
sinus node syndrome. Their ages ranged 
from 39 to 69 years. Five were new im-
plants and one was a replacement. 
In all these cases the bipolar unit was 
converted to the unipolar mode using an 
anodal g round plate adjacent to the 
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pulse generator. This was done to main-
tain comparabil i ty w i th the AEC-ARCO 
series and wi th a homogeneous series of 
24 patients in whom the Medtronic 5945 
unipolar pulse generator had already 
been implanted.^ These patients were 
used for the contro l group. Their ages 
and range of disease matched the Med-
t ron ic nuclear test series much more 
closely than was possible in the AEC-
ARCO study. 
All procedures were done under local 
anesthesia. Transvenous endocard ia l 
leads were used in all 40 patients. 
Results 
There were no opera t i ve or post-
operative complicat ions in any of the pa-
tients. 
The five patients wi th AEC-ARCO units 
have been fo l lowed for over one year. 
All are alive and wel l . One patient in the 
control series died of causes unrelated 
to his pacemaker. 
Of the six patients wi th the Medtronic 
9000 units, one patient died at home of 
unknown causes. No autopsy was ob-
ta ined bu t the pu lse gene ra to r was 
recovered, and re turned to the com-
pany. There was no evidence of pacer 
mal funct ion. Five patients are alive and 
wel l . In the control group, four patients 
died of causes unrelated to their pacers. 
One was shot to death as an innocent 
bystander in a service station ho ldup. 
Twenty are alive and wel l . 
Discussion 
It wi l l be many years before the true 
value and exact place of the nuclear 
pacemaker is established. However, it is 
clear, even at this early stage, that they 
are reliable. There is widespread publ ic 
acceptance of these devices. The pa-
tients that have them are p roud of their 
"unconvent iona l " pacemakers and there 
are many d isappo in ted pat ients w h o 
wou ld like to have one but do not meet 
the current protocol criteria. 
By January 1975, the AEC wi l l have de-
c ided on the s igni f icance o f the en-
vironmental impact of these devices fo l -
lowing a detailed study that has been 
going on for years. A decision wi l l be 
made at that t ime what restrictions if any 
— other than retrieval — wi l l be imposed 
on the use of nuclear pacemakers. 
References 
1. Smyth NPD, Keshishian JM, Baker N and 
Tarjan P: Physiological rationale for the 
clinical use of low output pacemakers. 
Medical Annals of DC 43:May, 1974 
2. Center S and Tarjan P: The clinical applica-
tion of low-output pacemakers. J Thorac 
Cardiovasc Surg 64:6, 1972 
3. Furman S, Denize A, Escher DJW and 
Schwedel JB: Energy consumption for car-
diac stimulation as a function of pulse du-
ration. J Surg Res 6:10, 1966 
4. Chardack WM, Baken EE, Bolduc L, Giori 
FA and Gage AA: Magnetically actuated 
pulse width control for implantable 
pacemakers. Ann Cardiol Angeiol (Paris) 
20:4, 1972 
Smyth NPD, Alferness C, Shearon L et al: 
Clinical evaluation of a new pulse 
generator using narrow width for battery 
energy conservation. / Thorac Cardiovasc 
Surg. 68:471, 1974 
Furman S, Parker W, Esche DJW and Sol-
omon N: Endocardial threshold of cardiac 
stimulation as a function of electrode sur-
face area. J Surg Res 8:161, 1968 
Kolenik SA, Hursen TF and Stevens DA: 
Nuclear pacemaker safety criteria. Associa-
t ion for Advancement of Medical In-
strumentation, 7th Annual Meeting, April 
24-26, 1972 
Pennington H, Hursen TF, Frommer PL and 
Morrow Ag: Animal implanted nuclear 
powered pacemakers. American Nuclear 
Society Winter Meeting, November 18, 
1970, Washington, DC 
116 
